ZLD Share Price Performance
AU$0.35
-0.40 (-53.33%)
Price AU$0.35
Share PriceAU$0.35
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year
Nov 08
Zelira Therapeutics Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ZLD Community Narratives
There are no narratives available yet.
Zelira Therapeutics Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.30
- Gross Margin
- -122,400.15%
- Net Profit Margin
- -553,029.27%
- Debt/Equity Ratio
- -46.4%
Zelira Therapeutics Limited Competitors
Snowflake Analysis
About ZLD
- Founded
- 2003
- Employees
- n/a
- CEO
- WebsiteView website
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 5.3%
- 1 Year: 8.9%
- Year to Date: 9.5%
The Materials sector gained 3.8% while the market remained flat over the last week. Meanwhile, the market is actually up 8.9% over the past year. Looking forward, earnings are forecast to grow by 12% annually. Market details ›